Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have been given an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus target price of $34.33 for the company, according to Zacks. Zacks has also given Deciphera Pharmaceuticals an industry rank of 111 out of 265 based on the ratings given to related companies.

A number of equities research analysts have weighed in on DCPH shares. Nomura started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $57.00 target price for the company. Piper Jaffray Companies started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “overweight” rating and a $35.00 target price for the company. JMP Securities started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “outperform” rating and a $38.00 target price for the company. J P Morgan Chase & Co started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “overweight” rating and a $30.00 target price for the company. Finally, Instinet started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $57.00 target price for the company.

In related news, major shareholder New Leaf Venture Management Ii acquired 375,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Monday, October 2nd. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $6,375,000.00. The purchase was disclosed in a filing with the SEC, which is available through this link.

Several large investors have recently bought and sold shares of DCPH. Emerald Advisers Inc. PA purchased a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth $6,661,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth $5,548,000. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth $2,172,000. SG Americas Securities LLC purchased a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth $143,000. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth $1,424,000. Hedge funds and other institutional investors own 5.10% of the company’s stock.

WARNING: “Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Receives Average Rating of “Strong Buy” from Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/21/zacks-deciphera-pharmaceuticals-inc-dcph-receives-average-rating-of-strong-buy-from-analysts.html.

Shares of Deciphera Pharmaceuticals (NASDAQ DCPH) traded up $0.25 during midday trading on Tuesday, reaching $21.07. 161,110 shares of the company were exchanged, compared to its average volume of 211,953. Deciphera Pharmaceuticals has a 52 week low of $16.11 and a 52 week high of $24.50.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, November 14th. The company reported ($5.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($5.30). analysts anticipate that Deciphera Pharmaceuticals will post -2.13 earnings per share for the current year.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.